Antibodies against MYC-Associated Zinc Finger Protein: An Independent Marker in Acute Coronary Syndrome?

Frontiers in Immunology

Torsten Witte¹  Diana Ernst¹  Reinhold E. Schmidt¹  Niklas T. Baerlecken¹  Christian Widera²  Lars Wallentin³  Wolfgang Schlumberger⁴  Cornelia Daehnrich⁴  Katja Gabrysch⁵ 

[1] Clinic of Rheumatology and Immunology, Hannover Medical School, Hannover, Germany;Department of Cardiology, Heart Center Oldenburg, European Medical School Oldenburg-Groningen, Carl von Ossietzky University Oldenburg, Oldenburg, Germany;Department of Medical Sciences, Cardiology, Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden;Euroimmun, Medizinische Labordiagnostika AG, Lübeck, Germany;Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden;

关键词: antibodies;    MYC-associated zinc finger protein;    acute coronary syndrome;    cardiac risk factor;    atherosclerosis;   

DOI  :  10.3389/fimmu.2017.01595

来源: DOAJ

【 摘 要 】

IntroductionAtherosclerosis is considered the pathophysiology underlying cardiovascular (CVD), cerebrovascular, and peripheral vascular diseases. Evidence supporting an autoimmune component is emerging, with imaging studies correlating MYC-associated zinc finger protein antibody (MAZ-Ab) optical density (OD) with plaque activity. This study compares MAZ-Ab OD on ELISA testing among patients presenting with acute coronary syndromes (ACSs) to healthy controls and investigates the association of MAZ-Ab to traditional CVD risk factors.MethodsPatients admitted with ACSs between August 2007 and July 2011 were included. Serum samples taken at presentation were retrospectively tested for MAZ-Ab and compared with serum from healthy volunteers with no CVD risk factors. Large-scale assessment of post-ACS prognostic relevance was performed using the established PLATO cohort.ResultsIn total 174 ACS patients and 96 controls were included. Among ACS patients, median MAZ-Ab OD was higher compared with controls (0.46 vs. 0.27; p = 0.001). Although the majority of ACS patients (116/174; 67%) had suffered from a ST-elevation myocardial infarction, no significant differences in MAZ-Ab titers were evident between ACS subtypes (p = 0.682). No associations between MAZ-Ab OD and conventional CVD risk factors were identified. Large-scale testing revealed no prognostic stratification regarding reinfarction (OR 1.04 [95% CI: 0.94–1.16]; p = 0.436).ConclusionMAZ-Ab OD was higher or all ACS phenotypes compared with controls. Given current understanding of MAZ-Ab function, these findings support an autoimmune component to CVD independent of conventional risk factors and indeed the extent of end-organ damage.

【 授权许可】

Unknown